EXPERIENCE IN USING A GLYCYRRHIZIC ACID PREPARATION IN YOUNG WOMEN WITH PERSISTENT PAPILLOMAVIRUS INFECTION
- Authors: SHARGORODSKAYA A.V1, LESHKINA G.V2, SHIPULINA O.Y.2, LOPATINA T.V1, ROGOVSKAYA S.I3
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
- Russian Medical Academy of Postgraduate Education
- Issue: No 2 (2013)
- Pages: 119-123
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246997
- ID: 246997
Cite item
Open Access
Access granted
Abstract
Objective. To study the efficacy of a glycyrrhizic acid preparation used in young women with persistent papillomavirus infection (PVI). Subjects and methods. 460 female students (mean age 22.4 years) were examined for 13 high-risk human papillomavirus (HPV) types and types 6/11 by multiplex real-time PCR. Ninety-one girls of the HPV-positive subjects were retested after 10-16 months. Fifty-six patients with persistent PVI were divided into 2 groups: 1) 25 patients were treated with a glycyrrhizic acid preparation for 3 months; 2) 31 untreated girls who formed a control group. The treatment results were assessed by CPR testing and PAP test 3 and 6 months later. Results. The overall prevalence of HPV among the young women was 30.9% (15.1% of the girls with normal cytology and 85.4% of those with low-grade squamous intraepithelial lesion (LSIL). Following 10—16 months, virus DNA elimination occurred in 35 (38.5%) persons, the manifestations of LSIL persisted in 12 (34.3%) patients. During glycyrrhizic acid treatment, there was a 2-fold reduction in the number of patients with the clinical manifestations of cervicitis, an improvement in PAP test results to the normal values in 29% of the women, and a decrease in the number of atypical changes from 40 to 16%, as evidenced by colposcopy. The HPV elimination rates within 6 months were 40 and 29% in the treatment and control groups, respectively.
Full Text
About the authors
A. V SHARGORODSKAYA
I.M. Sechenov First Moscow State Medical University
Email: anna.shargo@gmail.com
G. V LESHKINA
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
O. Yu SHIPULINA
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: Olga.shipulina@pcr.ru
T. V LOPATINA
I.M. Sechenov First Moscow State Medical University
S. I ROGOVSKAYA
Russian Medical Academy of Postgraduate Education
Email: E-maihsrogovskaya@maM.ru
References
- Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., Markowitz L.E. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297(8): 813-9.
- Burd E.M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 2003; 16(1): 1-17.
- Gilson R.J.S., Mindel A. Sexually transmitted infections. Br. Med. J. 2001; 322: 1160-4.
- Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E. et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001; 285(23): 2995-3002.
- Lowy D.R., Solomon D., Hildesheim A., Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 2008; 113(7, Suppl.): 1980-93.
- Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002; 55: 244-65.
- Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 2003; 157(3): 218-26.
- Sharma R.K., Srivastava A.K., Yolcu E.S., MacLeod K.J., Schabowsky R.H., Madireddi S., Shirwan H. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine. 2010; 28(36): 5794-802.
- Radaelli A., Pozzi E., Pacchioni S., Zanotto C., Morghen Cde G. Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. J. Transl. Med. 2010; 8:40.
- Seo S.H., Jin H.T., Park S.H., Youn J.I., Sung Y.C. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine. 2009; 27(42): 5906-12.
- Gupta V.K., Fatima A., Faridi U., Negi A.S., Shanker K., Kumar J.K. et al. Antimicrobial potential of Glycyrrhiza glabra roots. J Ethnopharmacol. 2008; 116(2): 377-80.
- Baltina L.A. Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. Curr. Med. Chem. 2003; 10(2): 155-71.
- Gao X., Wang W., Wei S., Li W. Review of pharmacological effects of Glycyrrhiza radix and its bioactive compounds. Zhongguo Zhong Yao Za Zhi. 2009; 34(21): 2695-700.
- Голованова В.А., Гуркин Ю.А., Новик В.И. В кн.: Актуальные вопросы детской и подростковой гинекологии: Материалы и тезисы докладов Всероссийской научно-практической конференции 22-24 сентября 1998, Новосибирск. Новосибирск; 1998:148-50.
- Кулаков В.И., Савельева Г.М., Манухин И.Б., ред. Гинекология. Национальное руководство. М.: ГЭОТАР-Медиа; 2009. 1088 с.
- Новиков А.И., Кононов А.В., Ваганова И.Г. Инфекции, передаваемые половым путем, и экзоцервикс. М.: Медицина; 2002. 176 с.
Supplementary files
